TINAVI(SH:688277)2025-04-28 15:15Revenue and Profitability - The company's revenue for Q1 2025 reached ¥58,583,819.68, representing a 102.40% increase compared to ¥28,944,718.96 in the same period last year[4] - The net profit attributable to shareholders was -¥13,204,889.44, a decline from -¥10,063,239.85 year-on-year[4] - The basic and diluted earnings per share were both -¥0.03, a decrease of 50.00% compared to -¥0.02 in the previous year[4] - Net loss for Q1 2025 was ¥14,378,611.68, compared to a net loss of ¥10,063,239.85 in Q1 2024, indicating a worsening of 42.5%[20] Research and Development - Research and development (R&D) expenses totaled ¥28,838,595.82, accounting for 49.23% of revenue, down from 95.45% in the previous year, a decrease of 46.22 percentage points[5] - The company plans to continue focusing on R&D while managing costs to improve profitability in future quarters[8] - Research and development expenses for Q1 2025 were ¥25,323,317.05, slightly down from ¥25,891,190.61 in Q1 2024, indicating a decrease of 2.2%[18] Cash Flow and Liquidity - The net cash flow from operating activities improved by 71.30%, amounting to -¥14,337,816.54 compared to -¥49,952,267.09 in the same period last year[8] - Operating cash inflow for Q1 2025 totaled ¥82,390,014.85, compared to ¥54,280,843.27 in Q1 2024, representing an increase of 52%[20] - Cash outflow from operating activities in Q1 2025 was ¥96,727,831.39, a decrease from ¥104,233,110.36 in Q1 2024, showing a reduction of 7.2%[20] - The company reported a net increase in cash and cash equivalents of $17,662,284.60, compared to a decrease of -$31,834,713.79 in the prior period[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,733,799,388.11, an increase of 2.49% from ¥1,691,716,774.29 at the end of the previous year[5] - Total liabilities as of the latest reporting period amounted to ¥413,580,571.19, slightly up from ¥411,577,279.87 in the previous period[16] - Non-current liabilities increased to ¥270,555,051.84 from ¥254,973,637.94, marking a rise of 6.1%[16] - The company's total equity reached ¥1,320,218,816.92, up from ¥1,280,139,494.42, reflecting a growth of 3.1%[16] Market and Product Development - The significant increase in revenue was attributed to higher sales of orthopedic surgical robots and increased income from providing technical services to medical institutions[8] - In Q1 2025, the Tianji orthopedic surgical robot performed over 11,000 surgeries, bringing the total to over 110,000 surgeries to date[12] - The orthopedic surgical navigation system received a Class III medical device registration certificate from the National Medical Products Administration, enhancing the company's product offerings and competitiveness[12] - The company aims to expand its product range to meet diverse clinical needs, enhancing its market position[12] - The company has established strategic partnerships to support market expansion and technological advancements[12] Non-Recurring Items - The company reported non-recurring gains of ¥18,041,873.99 after tax, primarily from government subsidies and other non-operating income[8] Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[22]